Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Inv. presentation
Quarterly results

Matinas BioPharma Holdings, Inc. (MTNB) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2023 8-K Quarterly results
Docs: "Matinas BioPharma Holdings, Inc. Condensed Consolidated Balance Sheets June 30, 2023 December 31, 2022 ASSETS: Current assets: Cash and cash equivalents $ 9,743 $ 6,830 Marketable debt securities 12,770 21,933 Restricted cash – security deposit 50 50 Prepaid expenses and other current assets 1,437 5,719 Total current assets 24,000 34,532 Non-current assets: Leasehold improvements and equipment – net 2,103 2,091 Operating lease right-of-use assets – net 3,345 3,613 Finance lease right-of-use assets – net 24 30 In-process research and development 3,017 3,017 Goodwill 1,336 1,336 Restricted cash – security deposit 200 200 Total non-current assets 10,025 10,287 Total assets $ 34,025 $ 44,819 LIABILITIES AND STOCKHOLDERS’ EQUITY: Current liabilities: Accounts payable $ 604 $ 618 Accrued expens..."
04/18/2023 8-K Quarterly results
03/15/2023 8-K Quarterly results
Docs: "Matinas BioPharma Holdings, Inc. Consolidated Balance Sheets December 31, 2022 2021 ASSETS: Current assets: Cash and cash equivalents $ 6,830 $ 21,030 Marketable debt securities 21,933 28,592 Restricted cash – security deposit 50 50 Prepaid expenses and other current assets 5,719 1,321 Total current assets 34,532 50,993 Non-current assets: Leasehold improvements and equipment - net 2,091 1,538 Operating lease right-of-use assets - net 3,613 4,219 Finance lease right-of-use assets - net 30 23 In-process research and development 3,017 3,017 Goodwill 1,336 1,336 Restricted cash - security deposit 200 200 Total non-current assets 10,287 10,333 Total assets $ 44,819 $ 61,326 LIABILITIES AND STOCKHOLDERS’ EQUITY: Current liabilities: Accounts payable $ 618 $ 937 Accrued expenses and other liabil..."
01/30/2023 8-K Investor presentation
Docs: "Matinas BioPharma Provides Business Update and 2023 Strategic Outlook"
01/12/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Matinas BioPharma Announces Collaboration with National Resilience to Explore and Evaluate Novel LNC Platform Delivery Technology for Certain Nucleic Acids"
12/29/2022 8-K Quarterly results
11/14/2022 8-K Quarterly results
11/02/2022 8-K Quarterly results
10/21/2022 8-K Quarterly results
09/13/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
08/11/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
04/13/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
04/11/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "BioNTech and Matinas BioPharma Announce Exclusive Research Collaboration to Evaluate Novel Delivery Technology for mRNA-based Vaccines"
03/08/2022 8-K Quarterly results
01/25/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Matinas BioPharma Provides Business Update and 2022 Strategic Outlook"
12/16/2021 8-K Quarterly results
12/06/2021 8-K Quarterly results
11/08/2021 8-K Quarterly results
Docs: "Matinas BioPharma Reports Third Quarter 2021 Financial Results and Operational Highlights"
11/01/2021 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
09/20/2021 8-K Quarterly results
09/13/2021 8-K Quarterly results
08/10/2021 8-K Quarterly results
05/10/2021 8-K Quarterly results
03/29/2021 8-K Quarterly results
02/01/2021 8-K Quarterly results
01/27/2021 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
01/14/2021 8-K Quarterly results
12/28/2020 8-K Other Events  Interactive Data
12/01/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "###"
11/25/2020 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "###"
11/06/2020 8-K Quarterly results
Docs: "Source: Matinas BioPharma Holdings, Inc."
11/04/2020 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
10/19/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy